Week 1 Case Study Template 1.Identify two medication classes for the treatment of the condition strongly recommended and provide an example (drug name) for each:

The Clinical Practice Guideline development group for allergic rhinitis strongly recommends intranasal steroids and oral second-generation antihistamines. Intranasal steroids are indicated for adults and children over 2 years of age for management of seasonal and perennial allergic rhinitis. An example of an intranasal steroid is fluticasone or Flonase. Oral second-generation antihistamines are used for the relief of nasal and non-nasal symptoms of allergies. An example of oral second-generation antihistamine is loratadine or Claritin (Seidman et al., 2015). 2.Describe the mechanism of action for each of the medication classes identified above: Fluticasone is a corticosteroid that has a fluorocarbothioate ester bond at the 17-carbon position and has exceptionally powerful vasoconstrictive and anti-inflammatory effects. Fluticasone has a direct local vasoconstriction impact as well as anti-inflammatory effects. It can prevent the onset of inflammation by inhibiting vasodilation, vascular permeability, and leukocyte emigration. Fluticasone inhibits inflammatory cells like eosinophils, monocytes, mast cells, macrophages, and dendritic cells by decreasing the amount of these cells as well as the cytokines they produce. This medicine also boosts beta-2 receptors on smooth muscle in the airways and lowers mucus gland secretions (Remien & Bowman, 2023). Loratadine is a second-generation antihistamine with properties of selective antagonistic to peripheral histamine H1 receptors. Loratadine preferentially inhibits H1-receptors on respiratory smooth muscle cells, vascular endothelial cells, gastrointestinal tract cells, and immunological cells. It lowers vascular permeability (prevents edema and flushing), smooth muscle tone (bronchodilation), and peripheral nociceptive receptor activation (reduces pain and itch). Second-generation antihistamines, can suppress histamine release from mast cells and basophils at high concentrations, lowering ICAM-1 expression in epithelial cells and inhibiting